Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Department of Neurosurgery, McGovern Medical School, University of Texas Health, Houston, TX 77030, USA.
Curr Oncol. 2024 Sep 25;31(10):5737-5751. doi: 10.3390/curroncol31100426.
Targeting the interleukin-6 (IL-6)/glycoprotein 130 (GP130) signaling pathway holds significant promise for cancer therapy given its essential role in the survival and progression of various cancer types. We have identified that bazedoxifene (BZA), a Food and Drug Administration (FDA)-approved drug used for the prevention of postmenopausal osteoporosis, when combined with conjugated estrogens in Duavee, also has a novel function as an inhibitor of IL-6/GP130 interaction. BZA is currently under investigation for its potential anticancer therapeutic function through the inhibition of the IL-6/GP130 pathway. Numerous studies have highlighted the efficacy of BZA (monotherapy or combined with other chemotherapy drugs) in impeding progression across multiple cancers. In this review, we mainly focus on the anticancer activity of BZA and the underlying anticancer mechanism through inhibition of the IL-6/GP130 pathway, aiming to provide valuable insights for the design and execution of further research and the potential repositioning of BZA in oncological clinical trials.
靶向白细胞介素-6（IL-6）/糖蛋白 130（GP130）信号通路在各种癌症类型的生存和进展中发挥着重要作用，因此在癌症治疗方面具有很大的潜力。我们已经发现，他莫昔芬（BZA），一种已被美国食品和药物管理局（FDA）批准用于预防绝经后骨质疏松症的药物，当与 Duavee 中的结合雌激素联合使用时，也具有抑制 IL-6/GP130 相互作用的新功能。BZA 目前正在通过抑制 IL-6/GP130 通路来研究其作为潜在抗癌治疗药物的功能。许多研究强调了 BZA（单独使用或与其他化疗药物联合使用）在阻止多种癌症进展方面的功效。在这篇综述中，我们主要关注 BZA 的抗癌活性及其通过抑制 IL-6/GP130 通路的潜在抗癌机制，旨在为进一步的研究设计和执行以及 BZA 在肿瘤学临床试验中的潜在重新定位提供有价值的见解。
